Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Unveiling the Financial and Strategic Position of Eli Lilly and Co in 2024
The market rally stumbled ahead of the Fed meeting. Amazon and AI plays Super Micro and AMD reported earnings late.